当前位置: 首页 > 期刊 > 《新医学》 > 20202
编号:13511023
GPD1L在肾透明细胞癌中的表达及其临床意义(4)
http://www.100md.com 2020年2月1日 《新医学》 20202
     [7] Sulaiman SA, Abu N, Ab-Mutalib NS, Low TY, Jamal R. Signatures of gene expression, DNA methylation and microRNAs of hepatocellular carcinoma with vascular invasion. Future Oncol, 2019, 15(22):2603-2617.

    [8] Barata PC, Rini BI. Treatment of renal cell carcinoma: current status and future directions. CA Cancer J Clin, 2017, 67(6):507-524.

    [9] Li QK, Pavlovich CP, Zhang H, Kinsinger CR, Chan DW. Challenges and opportunities in the proteomic characterization of clear cell renal cell carcinoma (ccRCC): a critical step towards the personalized care of renal cancers. Semin Cancer Biol, 2019, 55:8-15.

    [10] Kelly TJ, Souza AL, Clish CB, Puigserver P. A hypoxia-induced positive feedback loop promotes hypoxia-inducible factor 1alpha stability through miR-210 suppression of glycerol-3-phosphate dehydrogenase 1-like. Mol Cell Biol, 2011, 31(13):2696-2706.

    [11] Sch?del J, Grampp S, Maher ER, Moch H, Ratcliffe PJ, Russo P, Mole DR. Hypoxia, Hypoxia-inducible transcription factors, and renal cancer. Eur Urol, 2016, 69(4):646-657.

    [12] Costales MG, Haga CL, Velagapudi SP, Childs-Disney JL, Phinney DG, Disney MD. Small molecule inhibition of microRNA-210 reprograms an oncogenic hypoxic circuit. J Am Chem Soc, 2017, 139(9):3446-3455.

    (收稿日期:2019-09-18)

    (本文編辑:林燕薇), 百拇医药(刘仁?许晓明?罗勇?冯源发?周瑞?钟惟德)
上一页1 2 3 4